Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ranitidine
Drug ID BADD_D01913
Description Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries.[A176843] Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
Indications and Usage This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.[L10818,L10821]
Marketing Status approved; withdrawn
ATC Code Not Available
DrugBank ID DB00863
KEGG ID D00422
MeSH ID D011899
PubChem ID 3001055
TTD Drug ID D0B8WN
NDC Product Code 43353-445; 53746-253; 69842-869; 55111-404; 68462-249; 71713-203; 62207-773; 68196-985; 0121-4727; 50268-721; 63868-482; 65162-254; 69842-871; 71335-1327; 0121-0727; 43598-808; 68462-248; 0904-6921; 53746-254; 62207-774; 71335-1621; 11673-849; 27241-109; 30142-505; 45865-416; 63868-480; 65162-664; 67296-1586; 0904-6715; 64679-740; 65162-253; 70000-0033; 55111-131; 64679-741; 27241-110
UNII 884KT10YB7
Synonyms Ranitidine | Ranitidin | N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine | Biotidin | Ranisen | Sostril | Zantac | Zantic | AH-19065 | AH 19065 | AH19065 | Ranitidine Hydrochloride | Hydrochloride, Ranitidine
Chemical Information
Molecular Formula C13H22N4O3S
CAS Registry Number 82530-72-1
SMILES CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Emotional distress19.04.02.008--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Lung cancer metastatic22.08.01.004; 16.19.02.0030.000050%Not Available
Dysstasia15.03.05.011; 17.02.02.012; 08.01.03.089--Not Available
Gastrointestinal stromal tumour16.13.04.008; 07.21.04.0030.000175%Not Available
Self-injurious ideation19.12.01.007--Not Available
Prostatomegaly21.04.01.0020.000050%Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Adenocarcinoma pancreas07.21.09.003; 16.13.10.0020.000038%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Type IV hypersensitivity reaction10.01.03.022--Not Available
Bone cancer metastatic15.09.03.004; 16.29.02.0010.000088%Not Available
Hypertensive nephropathy24.08.05.003; 20.01.08.0040.000025%Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.000025%Not Available
Temperature intolerance08.01.09.022--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Testis cancer21.13.02.001; 16.25.03.0010.000538%Not Available
Breast cancer female21.05.01.011; 16.10.01.0040.001263%Not Available
Dysplasia08.03.04.0070.000025%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.011969%Not Available
Intestinal mass07.11.01.0100.000038%Not Available
Prostate cancer21.04.02.002; 16.25.01.0010.034868%Not Available
Abdominal hernia07.16.06.005--Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.000988%Not Available
Breast disorder21.05.04.0040.000025%Not Available
Gastrointestinal neoplasm16.13.11.001; 07.21.04.0020.000025%Not Available
Iris disorder06.06.06.0050.000025%Not Available
Metastatic neoplasm16.16.01.007--Not Available
Motor dysfunction17.01.02.031; 15.05.06.006--Not Available
Nasopharyngeal cancer22.08.02.005; 16.19.05.0010.000075%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene